Zacks Investment Research upgraded shares of Fibrocell Science (NASDAQ:FCSC) from a hold rating to a buy rating in a research note published on Thursday morning. The brokerage currently has $1.00 price objective on the stock.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
Separately, HC Wainwright set a $6.00 price objective on shares of Fibrocell Science and gave the company a buy rating in a report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $4.00.
Fibrocell Science (NASDAQ:FCSC) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.07. analysts predict that Fibrocell Science will post -1.63 earnings per share for the current year.
In other news, major shareholder Randal J. Kirk purchased 2,727,273 shares of the stock in a transaction that occurred on Monday, December 11th. The shares were purchased at an average cost of $0.77 per share, with a total value of $2,100,000.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.10% of the company’s stock.
A hedge fund recently raised its stake in Fibrocell Science stock. Parametric Portfolio Associates LLC increased its position in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 264.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 48,259 shares of the company’s stock after buying an additional 35,000 shares during the period. Parametric Portfolio Associates LLC owned 0.33% of Fibrocell Science worth $194,000 as of its most recent filing with the SEC. 31.57% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.com-unik.info/2018/01/22/fibrocell-science-fcsc-stock-rating-upgraded-by-zacks-investment-research.html.
About Fibrocell Science
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.